These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34465857)

  • 1. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.
    Pontes-da-Silva RM; de Souza Marinho T; de Macedo Cardoso LE; Mandarim-de-Lacerda CA; Aguila MB
    Int J Obes (Lond); 2022 Jan; 46(1):21-29. PubMed ID: 34465857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice.
    Martins FF; Marinho TS; Cardoso LEM; Barbosa-da-Silva S; Souza-Mello V; Aguila MB; Mandarim-de-Lacerda CA
    Cell Biochem Funct; 2022 Dec; 40(8):903-913. PubMed ID: 36169111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
    Reis-Barbosa PH; Marcondes-de-Castro IA; Marinho TS; Aguila MB; Mandarim-de-Lacerda CA
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101922. PubMed ID: 35427802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-steatotic linagliptin pleiotropic effects encompasses suppression of de novo lipogenesis and ER stress in high-fat-fed mice.
    Santos FO; Correia BRO; Marinho TS; Barbosa-da-Silva S; Mandarim-de-Lacerda CA; Souza-Mello V
    Mol Cell Endocrinol; 2020 Jun; 509():110804. PubMed ID: 32259637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotadutide effect in liver and adipose tissue in obese mice.
    Marcondes-de-Castro IA; Oliveira TF; Spezani R; Marinho TS; Cardoso LEM; Aguila MB; Mandarim-de-Lacerda CA
    J Mol Endocrinol; 2023 Apr; 70(3):. PubMed ID: 36753306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
    J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress.
    Petito-da-Silva TI; Souza-Mello V; Barbosa-da-Silva S
    Mol Cell Endocrinol; 2019 Dec; 498():110539. PubMed ID: 31419466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
    Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice.
    Barbosa-da-Silva S; Souza-Mello V; Magliano DC; Marinho Tde S; Aguila MB; Mandarim-de-Lacerda CA
    Life Sci; 2015 Apr; 127():73-81. PubMed ID: 25748419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatment.
    Marinho TS; Martins FF; Cardoso LEM; Aguila MB; Mandarim-de-Lacerda CA
    Biochimie; 2022 Feb; 193():126-136. PubMed ID: 34742857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY
    Kloock S; Haerting N; Herzog G; Oertel M; Geiger N; Geier A; Sequeira V; Nickel A; Kohlhaas M; Fassnacht M; Dischinger U
    Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.
    Fang T; Huang S; Chen Y; Chen Z; Chen J; Hu W
    Exp Clin Endocrinol Diabetes; 2021 Sep; 129(9):625-633. PubMed ID: 32961563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent fasting, high-intensity interval training, or a combination of both have beneficial effects in obese mice with nonalcoholic fatty liver disease.
    de Castro-de-Paiva P; Marinho TS; Mandarim-de-Lacerda CA; Aguila MB
    J Nutr Biochem; 2022 Jun; 104():108997. PubMed ID: 35331900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity.
    Kim SQ; Kim J; Choi M; Kim Y; Kim S; Kim KH
    Biochem Biophys Res Commun; 2023 Dec; 688():149164. PubMed ID: 37951155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice.
    Rodriguez-Echevarria R; Macias-Barragan J; Parra-Vargas M; Davila-Rodriguez JR; Amezcua-Galvez E; Armendariz-Borunda J
    World J Gastroenterol; 2018 Jan; 24(4):461-474. PubMed ID: 29398867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.
    Thorsø Larsen A; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2023 Sep; 954():175837. PubMed ID: 37329973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.